# XENOHELIX

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/xenohelix

- Industry: Biotechnology
- Headquarters: Incheon, South Korea
- Website: www.xenohelix.com
- Latest round: Series A (Sep 1, 2019)
- Investors on record: 2

## About

Based in Incheon, South Korea, and founded in 2019 by CEO Sungwook, XENOHELIX operates as a developer of molecular diagnostic technology and kits used for screening and diagnosing various diseases related to microRNA. In September 2019, XENOHELIX raised funding from investors KB Investment and Korea Tech Incubator for Startups, being selected for the Accelerator Investment-Driven Tech Incubator Programme.

XENOHELIX offers products and services for the early diagnosis of serious diseases such as degenerative brain diseases and cancer, such as RNA Purification, PCR/qPCR, exosomes, alpha-synuclein, and more. The company also offers the XENO ApoE Genotyping Kit for the diagnosis of Alzheimer’s disease, which uses a fluorescent probe to determine the polymorphism in the amino acid sequence of ApoE.

## Funding rounds

- Series A, Sep 1, 2019 — KB Investment, Korea Tech Incubator for Startup

## Investors

- KB Investment (https://capitalatlas.ai/funds/kb-investment) — Series A
- Korea Tech Incubator for Startup — Series A